Medical Device Clinical Evaluation (MDCE)Working Group Update

National Medical Product Administration, China

September 14th, 2021

Summary of previous work

Extension item

Mar. 2018-

Sep. 2019

Clinical Evaluation Work Item Sep. 2019-

Mar. 2020

Post-Market Clinical Follow-Up Studies

Work Item



Documents developed

IMDRF MDCE WG/N55 FINAL:2019 (formerly GHTF/SG5/N1R8:2007)



FINAL International Medi

Title: Clinical Evidence - Key

Authoring Group: Medical De

Date: 10 October 2019

This document was produced by the Inter no restrictions on the reproduction or use document, in part or in whole, into another English, does not convey or represent an Device Regulators Forum.

Copyright © 2019 by the International Me

IMDRF MDCE WG/N56FINAL:2019 (formerly GHTF/SG5/N2R8:2007)



FINAL DOCU

International Medical Devic

Title: Clinical Evaluation

Authoring Group: Medical Device Clir

Date: 10 October 2019

Ele

This document was produced by the International Mec no restrictions on the reproduction or use of this docur document, in part or in whole, into another document, English, does not convey or represent an endorsement Device Regulators Forum.

Copyright @ 2019 by the International Medical Device

IMDRF MDCE WG/N57FINAL:2019 (formerly GHTF/SG5/N3:2010)



FINAL DOCUMEN

International Medical Device R

Title: Clinical Investigation

Authoring Group: Medical Device Clinical

Date: 10 October 2019



FINAL DOCUMENT

Title: Post-Market Clinical Follow-Up Studies

Authoring Group: Medical Device Clinical Evaluation Working Group

Date: 25 March, 2021

Elena N

This document was produced by the International Medical I no restrictions on the reproduction or use of this document document, in part or in whole, into another document, or its English, does not convey or represent an endorsement of an Device Regulators Forum.

Dr Jeong-Rim Lee, IMDRF Chair

IMDRF MDCE WG/N65FINAL:2021

The document herein was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in Copyright © 2019 by the International Medical Device Reg whole. into any other document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

Copyright © 2021 by the International Medical Device Regulators Forum

Working Group Members 2018-2019

Australia: Simon Singer

Brazil: Alessandro Ferreira do Nascimento, Leticia Barel Filier

Canada: Amanda Jones

China: Yinghui Liu (Chair), Shan Ju, Yawen Wang

EU: Camilla Fleetcroft, Gwennaelle EVEN

Japan: Yumiko Aoyagi, Daisuke Tanaka, Mami Ho, Daisuke Fujisawa

Russia: Valeeva Aisylu, Kurtukov Yaroslav

Singapore: Low Lai Peng

South Korea: Youngsook Choi, Youngmin Han

The United States: Soma Kalb, Minerva Hughes

WTO/PAHO: Micaela Dominguez

DITTA: Keiichiro Ozawa, Leo Hovestadt, Bradley Matsubara

GMTA: Michael Pfleger, Robin Newman, Theodore Lystig

Working Group Members 2019-2021

Australia:

<u>Simon Singer</u> Jeffrey Brownscombe

Brazil:

Alessandro Ferreira do Nascimento

Canada:

Amanda Jones Patrick Fandja

China:

Yinghui Liu Shan Ju Yawen Wang

Europe:

Gwennaelle Even Tom Melvin Paul Piscoi

Japan:

Taku Oohara
Fumihito Takanashi
Mami Ho
Daisuke Fujisawa
Nobuhiro Handa
Haruka Yoshitake
Yuki Kimura
Yukari Namba
Mika Togashi

Russia:

Anna Dmitrieva

<u>Singapore</u>:

Low Lai Peng

South Korea:

Hee-jung Kim MOON, Sun-Young

The United States:

Minerva Hughes Nilsa Loyo-Berrios Adam Donat

PAHO:

Micaela Dominguez
Jose Medico

DITTA:

<u>Leo Hovestadt</u> <u>Keiichiro Ozawa</u> <u>Greg Leblanc</u>

GMTA:

Michael Pfleger Theodore Lystig



NWIE/NWIP submitted – MRCI & N5

Multi-Regional Clinical Investigation (MRCI)

Aim to increase the efficiency and effectiveness during pre-market medical device review by promoting global harmonization in general requirements on the planning, design and conduct of the MRCIs.

Reportable Events During Pre-Market Clinical Investigations(N5)

Aim to Harmonize a more tailored and fit for purpose regulatory model for recording and reporting adverse events that may occur during a clinical investigation. Adapt the requirements to current situation of IMDRF members, such as scope of reporting events, timing to report, contents of reports etc. Transfer detailed requirements from main body into informative attachment with necessary modification, reflecting the representative requirements of different jurisdictions.

<u>Unfortunately, the NWIP/NWIE did not discussed at MC meeting,</u> <u>because the MC considered that IVD work item has higher priority</u> <u>under current global situation.</u>

Further work plan

• MDCE working group will consider to apply for the MRCI & GHTF N5 work items after IVD work item is done.

OR

• Working group is also exploring new work items to consider, aligned with the IMDRF strategic plan 2021-2025.



Thanks for your attention